Announcement Overview
BioLineRx Ltd (NASDAQ:BLRX) disclosed a definitive agreement for a registered direct offering of 1,348,921 American Depositary Shares (ADS) at a price of $2.78 per ADS. The transaction is expected to generate gross proceeds of $3.75 million before deduction of fees and expenses. Chardan is serving as the exclusive placement agent, and the closing is anticipated on or about 31 August 2026, subject to customary closing conditions.
Offering Structure
In addition to the primary ADS sale, the company will issue warrants that allow the purchaser to acquire up to 2,023,382 additional ADS at the same exercise price of $2.78 per ADS. These warrants will expire five years from the date of issuance. Each ADS represents 600 ordinary shares of BioLineRx.
Warrant Amendment
Concurrent with the offering, BioLineRx entered into a warrant amendment with the investor to modify outstanding warrants covering 277,273 ADS. The amended warrants now have an exercise price of $2.78 per ADS and an extended expiration date of 31 August 2031, which will become effective upon closing of the offering.
Use of Proceeds
The company stated that net proceeds from the offering will be allocated to research and development activities, working capital requirements, and general corporate purposes.
Market Reaction
Following the announcement, BioLineRx shares declined 4.4 % in pre‑market trading on Friday, reflecting the pricing of the ADS below recent market levels.
Business Context
BioLineRx is a clinical‑stage biopharmaceutical firm focused on oncology and rare diseases. Its lead asset, GLIX1, is an oral small‑molecule targeting DNA‑damage response pathways in glioblastoma and other solid tumours, with a Phase 1/2a trial launched in the first quarter of 2026. The company’s first approved product, APHEXDA (motixafortide), is indicated in the United States for stem‑cell mobilisation in autologous transplantation for multiple myeloma.